Pharmamarketeer
wet- en regelgeving

Eisai’s antiepileptic drug receives FDA approval to treat partial-onset seizures in pediatric patients

2 oktober 2018
News-Medical.Net

Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. received approval from the U.S. Food and Drug Administration for an indication expansion for Eisai’s antiepileptic drug Fycompa (perampanel) to cover partial-onset seizures in pediatric patients with epilepsy 4 years of age and older.

Reageer

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)